

Title	Summary	Presenter	September 28 9:30-5	September 29 9:30-5
SARS CoV-2: Rising to the Testing Challenge in the United States	This session will explore SARS-CoV-2 testing methodologies, including molecular, antigen, and serological approaches, as well as critical considerations when keeping up with this adaptable and ever-changing virus.	Allyson Kozak	10:00 AM	2:00 PM
Trends in Sepsis Management and Antibiotic Treatment Decisions	This session describe the current trends in sepsis management, associated biomarkers, and how they can be applied to the clinical decision making process. Additionally, this presentation discusses the growing health concern of antibiotic resistance.	Justin Jones	3:00 PM	11:00 AM
Biomarkers in Alzheimer's Disease	This session will review biomarkers in Alzheimer's Disease and the clinical implications for early diagnosis and treatment	Chris Stamatkin	1:00 PM	10:00 AM
Cardiovascular disease in women	This session will discuss cardiac disease in women: differences in presentation, outcomes, and the utilization of biomarkers to improve diagnosis and outcomes	Alex Power	NA	1:00 PM
Advancement of Digital Health in the COVID-19 era	This session will discuss impact the pandemic had on telehealth and telemedicine adoption as well as the mobilization of digital applications beyond the pandemic	Denise Heaney	2:00 PM	NA
Public Health Perspective; post COVID-19	This session will describe key lessons learned in the public health sector during the COVID-19 pandemic and discuss how these lessons advocate for us to think differently about diagnostics in the future.	Denise Heaney	4:00 PM	NA
Pre-eclampsia: A collaborative perspective	This session will provide an overview of the pre-e disease state and how the healthcare team can work collaboratively to have an impact.	Laura Parnas	11:00 AM	NA

11:30 a.m. - 12:30 p.m.

September 28 Industry Workshop:

Improving the management of patients with preeclampsia using biomarkers: Everyone else is doing it, so why aren't we?

Speaker: Liza Kunz, MD, FACOG, Roche Medical & Scientific Affairs

Preeclampsia is a major cause of fetal and maternal morbidity and mortality, occurring in 2-8% of pregnancies worldwide. Multiple studies have demonstrated an imbalance of angiogenic factors with preeclampsia, sometimes as early as 5 weeks prior to the onset of symptoms. Outside of the United States, many countries have adopted biomarker analysis as part of the screening algorithm for preeclampsia. To date, testing is not yet clinically available in this country. Liza Kunz, a practicing maternal fetal medicine specialist, will speak to the challenge of diagnosing preeclampsia and outline the impact of biomarker analysis worldwide.

11:30 a.m.-12:30 p.m.

September 29 Industry Workshop:

It Takes a Team: A High Sensitivity Troponin Implementation Success Story

Speakers:

Josie B. Bowen, MD, FACEP, Emergency Physician, Novant Presbyterian Hospital

Nicole Osman, B.S. MLS (ASCP)cm, Vice President, Guthrie Laboratories

Jon Rittenberger, MD, Chief of Emergency Medicine, Guthrie Robert Packer Hospital

Over the last four years, many hospitals have incorporated high sensitivity troponins into their protocols to benefit their patients, practitioners and institutions. Moving from a conventional troponin assay to a high sensitivity troponin assay requires collaboration, alignment and education among multiple stakeholders. If your lab or institution is in the process of shifting to a high sensitivity troponin or is about to, come hear from lab professionals who have overcome the challenges they faced and successfully navigated this complex transition. Hear best practices and learn what implementation success is when converting to a high sensitivity troponin.